Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Laura Corsini

Dermatology Alexandria, VA Medical Doctor

NPI 1376957563 CMS profile 4944673

1900 N Beauregard St Ste 110, Alexandria, VA 22311

Open in the dashboard

General payments

$4,190

214 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Laura Corsini of Alexandria, VA is reported in the CMS Open Payments database as having received $4,190 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $781 42
2021 General $1,428 72
2020 General $517 28
2019 General $1,464 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Corsini
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Laura Corsini were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Laura Corsini Dermatology median Middle half National median
2019 $1,464 $454 $129–$1,240 $163
2020 $517 $235 $81–$756 $114
2021 $1,428 $377 $108–$1,108 $132
2022 $781 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AbbVie, Inc. $807 41 payments
  2. Galderma Laboratories, L.P. $607 33 payments
  3. Janssen Biotech, Inc. $540 28 payments
  4. Novartis Pharmaceuticals Corporation $373 19 payments
  5. Regeneron Healthcare Solutions, Inc. $242 12 payments
  6. Sun Pharmaceutical Industries Inc. $193 10 payments
  7. Lilly USA, LLC $186 9 payments
  8. Pfizer Inc. $157 9 payments
  9. LEO Pharma Inc. $148 10 payments
  10. UCB, Inc. $128 6 payments
  11. Other $807 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,995 210 payments
  2. Education $195 4 payments
Products named General payments · program years 2019–2022
  1. SKYRIZI $494 27 payments
  2. TREMFYA $367 18 payments
  3. HUMIRA $335 16 payments
  4. SOOLANTRA $294 18 payments
  5. EPIDUO FORTE $229 14 payments
  6. AKLIEF $211 13 payments
  7. DUPIXENT $207 10 payments
  8. COSENTYX $206 11 payments
  9. TALTZ $186 9 payments
  10. SIMPONI ARIA $173 10 payments
  11. Other $2,693 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

791

Median for Dermatology: 534

Drug cost

$21,760

Median for Dermatology: $67,151

Branded share of claims

1.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorouracil Generic 91 $5,849
Clobetasol Propionate Generic 129 $5,293
Doxycycline Hyclate Generic 105 $2,145
Pimecrolimus Generic 12 $1,637
Ketoconazole Generic 98 $1,453
Triamcinolone Acetonide Generic 152 $1,262
Fluocinonide Generic 53 $1,225
Clindamycin Phosphate Generic 25 $1,065
Metronidazole Generic 13 $841
Gentamicin Sulfate Generic 14 $408

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$206,017

Of which drugs: $27

Medicare patients

789

Average age 76

Services billed

3,579

475 women, 314 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 44%
Ischemic heart disease 30%
Osteoporosis 26%
Atrial fibrillation 17%
Cancer 17%
Diabetes 14%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 24 39 $27

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record